Xenon Pharmaceuticals
XENE
36.41
-0.16
-0.44%
Xenon Pharmaceuticals
US · XENE
#2361 by market cap
Listed 2015
36.41
-0.16
-0.44%
Live - 5344 symbols - heartbeat 378s ago
· 2026-10-08 08:29
Pre-market
36.25
-0.44%
After-hours
36.00
-1.13%
Overnight
36.40
-0.03%
- Market cap
- 3.53B
- P/E (TTM)i
- -7.68
- P/Bi
- 2.84
- EPSi
- -4.36
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on XENE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 37.45, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Margins
- Operating margin
- -4,974.27%
- Net margin
- -4,612.13%
Key ratios & quality
- Altman Z-Scorei
- 37.45
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 6.83M | 32.17M | 18.44M | 9.43M | 0 | 0 | 7.50M |
| Gross profit | -6.00M | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.41M | 10.80M | 12.94M | 21.97M | 32.81M | 46.54M | 68.90M | 79.63M |
| Research & development | 23.63M | 38.85M | 50.52M | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| Operating profit | -38.04M | -42.82M | -31.30M | -78.99M | -129.14M | -214.05M | -279.30M | -373.07M |
| Pretax profit | -34.52M | -41.62M | -29.09M | -78.89M | -125.26M | -182.69M | -238.42M | -344.89M |
| Tax | -24.00K | -23.00K | -257.00K | -6.00K | 118.00K | -292.00K | -4.09M | 1.02M |
| Net profit | -34.50M | -41.60M | -28.84M | -78.88M | -125.37M | -182.39M | -234.33M | -345.91M |
| Basic EPS | -2 | -2 | -1 | -2 | -2 | -3 | -3 | -4 |
| Diluted EPS | -1.63 | -1.54 | -0.81 | -1.77 | -2.06 | -2.73 | -3.01 | -4.36 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 7.50M | 0 | 0 | 0 | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 19.04M | 19.24M | 19.28M | 22.07M | 23.82M | 23.93M |
| Research & development | 61.20M | 74.99M | 77.05M | 87.70M | 88.51M | 99.22M |
| Operating profit | -72.74M | -94.23M | -96.34M | -109.77M | -112.33M | -123.16M |
| Pretax profit | -64.62M | -85.33M | -90.22M | -104.72M | -104.87M | -111.32M |
| Tax | 427.00K | -626.00K | 677.00K | 538.00K | -2.57M | -585.00K |
| Net profit | -65.05M | -84.71M | -90.90M | -105.26M | -102.30M | -110.74M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.83 | -1.07 | -1.15 | -1.31 | -1.17 | -1.11 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 121.33M | 144.87M | 181.78M | 559.02M | 600.30M | 644.96M | 635.26M | 560.65M |
| Cash & ST investments | 119.31M | 141.36M | 177.00M | 551.77M | 592.09M | 638.08M | 626.91M | 548.89M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 122.43M | 147.70M | 189.19M | 572.01M | 754.15M | 964.80M | 798.14M | 633.16M |
| Total current liabilities | 4.12M | 43.38M | 14.78M | 14.32M | 22.70M | 27.27M | 35.59M | 41.79M |
| Short-term debt | -- | 4.82M | 265.00K | 605.00K | 488.00K | 1.30M | 1.37M | 1.53M |
| Long-term debt | 15.01M | 10.89M | -- | -- | -- | -- | -- | -- |
| Total liabilities | 19,133,000.00 | 55,720,000.00 | 17,831,000.00 | 21,974,000.00 | 32,649,000.00 | 36,877,000.00 | 43,236,000.00 | 51,403,000.00 |
| Total equity | 103.30M | 91.98M | 171.36M | 550.03M | 721.50M | 927.92M | 754.90M | 581.76M |
| Retained earnings | -207.89M | -249.66M | -278.49M | -357.37M | -482.75M | -665.14M | -899.47M | -1.25B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 565.54M | 500.25M | 480.14M | 560.65M | 1.11B | 945.87M |
| Cash & ST investments | 549.63M | 487.55M | 462.27M | 548.89M | 1.09B | 930.69M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 743.28M | 674.28M | 607.84M | 633.16M | 1.39B | 1.30B |
| Total current liabilities | 32.03M | 33.05M | 38.34M | 41.79M | 39.82M | 45.01M |
| Short-term debt | 1.38M | 1.46M | 1.50M | 1.53M | 1.56M | 1.34M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 39,323,000.00 | 40,303,000.00 | 48,325,000.00 | 51,403,000.00 | 48,991,000.00 | 53,376,000.00 |
| Total equity | 703.96M | 633.98M | 559.51M | 581.76M | 1.34B | 1.24B |
| Retained earnings | -964.52M | -1.05B | -1.14B | -1.25B | -1.35B | -1.46B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -34.72M | -4.71M | -48.12M | -69.50M | -101.03M | -151.11M | -181.39M | -279.12M |
| Depreciation & amortization | 586.00K | 429.00K | 644.00K | 906.00K | 1.41M | 2.06M | 2.56M | 2.54M |
| Free cash flow | -35.23M | -5.95M | -50.76M | -71.55M | -103.92M | -156.73M | -184.46M | -279.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 102.85M | 27.40M | 102.46M | 447.28M | 277.77M | 353.49M | 12.08M | 112.15M |
| Ending cash balance | 67.75M | 24.76M | 45.01M | 175.69M | 57.24M | 148.64M | 142.71M | 199.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -61.65M | -64.23M | -71.75M | -81.48M | -88.90M | -95.39M |
| Depreciation & amortization | 659.00K | 632.00K | 641.00K | 611.00K | 587.00K | 558.00K |
| Free cash flow | -61.70M | -64.39M | -72.03M | -81.80M | -89.03M | -95.67M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 837.53M | 0 |
| Ending cash balance | 116.66M | 135.38M | 104.51M | 199.16M | 545.87M | 119.53M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -48.09 | -44.52 | -22.60 | -21.84 | -19.77 | -22.12 | -27.85 | -51.76 |
| ROA %i | -37.52 | -29.64 | -16.63 | -20.25 | -18.84 | -21.22 | -26.58 | -48.34 |
| ROIC %i | -41.20 | -37.90 | -22.27 | -21.62 | -20.49 | -25.13 | -32.37 | -54.48 |
| 5-year avg ROE %i | -- | -42.90 | -42.71 | -39.71 | -31.36 | -26.17 | -22.84 | -28.67 |
| EBIT margin %i | -- | -588.43 | -88.94 | -427.88 | -1,327.70 | -- | -- | -4,974.27 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 29.46 | 3.34 | 12.30 | 39.03 | 26.44 | 23.65 | 17.85 | 13.42 |
| Quick ratioi | 29.00 | 3.28 | 12.10 | 38.72 | 26.12 | 23.43 | 17.66 | 13.17 |
| Debt / assetsi | 12.26 | 11.14 | 1.75 | 1.44 | 1.38 | 1.13 | 1.13 | 1.25 |
| LT debt / equityi | 15.71 | 13.81 | 1.86 | 1.41 | 1.38 | 1.04 | 1.01 | 1.10 |
| Interest coveragei | -23.75 | -28.02 | -59.11 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | 55.88 | 369.40 | -- | 11.37 | -- | -- | -7.36 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -31.60 | -37.65 | -45.14 | -51.76 | -37.53 | -43.62 |
| ROA %i | -30.25 | -35.71 | -42.44 | -48.34 | -35.98 | -41.54 |
| ROIC %i | -35.95 | -41.79 | -48.99 | -54.48 | -39.72 | -46.49 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -3,906.60 | -4,241.60 | -4,543.73 | -4,974.27 | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 17.66 | 15.14 | 12.52 | 13.42 | 27.79 | 21.02 |
| Quick ratioi | 17.43 | 14.79 | 12.08 | 13.17 | 27.53 | 20.71 |
| Debt / assetsi | 1.17 | 1.29 | 1.37 | 1.25 | 0.54 | 0.50 |
| LT debt / equityi | 1.04 | 1.14 | 1.22 | 1.10 | 0.44 | 0.41 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovering, developing, and delivering life-changing therapeutics for patients in need100.00%
Region
Canada100.00%
Quote time 2026-10-08 08:29:12 · For reference only, not investment advice and not tailored to your situation.